Antidepressant efficacy of Agomelatine: Meta-analysis of placebo controlled and active comparator studies

Bagby, 2004, The Hamilton Depression Rating Scale: has the gold standard become a lead weight?, Am. J. Psychiatry, 161, 2163, 10.1176/appi.ajp.161.12.2163 Barbui, 2008, Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials, Can. Med. Assoc. J., 178, 296, 10.1503/cmaj.070693 Borenstein, 2011 Cipriani, 2018, Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, Focus, 16, 420, 10.1176/appi.focus.16407 Cohen, 1988, The t-test for means, 2, 20 Corruble, 2013, Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial, Int. J. Neuropsychopharmacol., 16, 2219, 10.1017/S1461145713000679 Deeks, 2019, Analysing data and undertaking meta‐analyses, 241 Demyttenaere, 2013, A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline, CNS Spectr., 18, 163, 10.1017/S1092852913000060 European Medicines Agency. 2012. Valdoxan (agomelatine). 〈www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000915/human_med_001123.jsp&mid=WC0b01ac058001d124〉. Eyding, 2010, Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials, Br. Med. J., 341, 4737, 10.1136/bmj.c4737 Hale, 2010, Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study, Int. Clin. Psychopharmacol., 25, 305, 10.1097/YIC.0b013e32833a86aa Hamilton, 1960, The Hamilton Depression Scale—accelerator or break on antidepressant drug discovery, Psychiatry, 23, 56 Heun, 2013, The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study, J. Clin. Psychiatry, 74, 587, 10.4088/JCP.12m08250 Hickie, 2011, Novel melatonin-based therapies: potential advances in the treatment of major depression, Lancet, 378, 621, 10.1016/S0140-6736(11)60095-0 Higgins, 2003, Measuring inconsistency in meta-analyses, Br. Med. J., 327, 557, 10.1136/bmj.327.7414.557 Higgins, 2008, Selecting studies and collecting data, 151 Higgins J.P., Altman D.G., 2020. Assessing risk of bias in included studies.Cochrane Handbook for Systematic Reviews of Interventions Version 5.4. 0 [updated September 2020]. The Cochrane Collaboration. Howland, 2011, A benefit-risk assessment of agomelatine in the treatment of major depression, Drug Saf., 34, 709, 10.2165/11593960-000000000-00000 Howland, 2011, Publication bias and outcome reporting bias: agomelatine as a case example, J. Psychosoc. Nurs. Ment. Health Serv., 49, 11, 10.3928/02793695-20110809-01 Huang, 2014, Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials, Aust. N. Z. J. Psychiatry, 48, 663, 10.1177/0004867414525837 Isacsson, 2012, Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression, Acta Psychiatr. Scand., 125, 453, 10.1111/j.1600-0447.2011.01815.x Kasper, 2010, The efficacy of agomelatine in previously treated depressed patients, Int. J. Psychiatry Clin. Pract., 14, 26 Kasper, 2013, Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control, Int. Clin. Psychopharmacol., 28, 12, 10.1097/YIC.0b013e328359768e Kennedy, 2006, Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, Eur. Neuropsychopharmacol., 16, 93, 10.1016/j.euroneuro.2005.09.002 Kennedy, 2008, A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR., J. Clin. Psychopharmacol., 28, 329, 10.1097/JCP.0b013e318172b48c Kennedy, 2010, Agomelatine in the treatment of major depressive disorder, CNS Drugs, 24, 479, 10.2165/11534420-000000000-00000 Kennedy, 2014, A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder, Eur. Neuropsychopharmacol., 24, 553, 10.1016/j.euroneuro.2014.01.006 Kennedy, 2016, Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months, Eur. Neuropsychopharmacol., 26, 378, 10.1016/j.euroneuro.2015.09.006 Kirsch, 2008, Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration, PLoS Med., 5, 45, 10.1371/journal.pmed.0050045 Koesters, 2013, Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials, Br. J. Psychiatry, 203, 179, 10.1192/bjp.bp.112.120196 Lemoine, 2007, Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine., J. Clin. Psychiatry, 68, 1723, 10.4088/JCP.v68n1112 Leucht, 2012, Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses, Br. J. Psychiatry, 200, 97, 10.1192/bjp.bp.111.096594 Loo, 2002, Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study, Int. Clin. Psychopharmacol., 17, 239, 10.1097/00004850-200209000-00004 Mathers, 2008 Mehta, 2017, Comparative efficacy of agomelatine versus sertraline in major depressive disorder in Himalayan region of India, Int. J. Basic Clin. Pharmacol., 6, 2358, 10.18203/2319-2003.ijbcp20174359 Moher, 2015, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement, Syst. Rev., 4, 1, 10.1186/2046-4053-4-1 Montgomery S., Åsberg M.A., 1977. A new depression scale designed to be sensitive to change. Acad. Department of Psychiatry, Guy's Hospital. Montgomery, 2004, Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study, Int. Clin. Psychopharmacol., 19, 271, 10.1097/01.yic.0000137184.64610.c8 Montgomery, 2007, Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine, Int. Clin. Psychopharmacol., 22, 283, 10.1097/YIC.0b013e3280c56b13 Moret, 2009, Problems associated with long-term treatment with selective serotonin reuptake inhibitors, J. Psychopharmacol., 23, 967, 10.1177/0269881108093582 Morssinkhof, 2020, Associations between sex hormones, sleep problems and depression: a systematic review, Neurosci. Biobehav. Rev., 118, 669, 10.1016/j.neubiorev.2020.08.006 Novartis Pharmaceuticals Corporation, Unpublished results. An 8-week, multicenter, randomized, double-blind, placebo-and paroxetine-controlled study of the efficacy, safety and tolerability of agomelatine 25 or 50mg given once daily in the treatment of Major Depressive Disorder (MDD). Study CAGO178A2303. Novartis. Pierre Olié, 2007, Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder, Int. J. Neuropsychopharmacol., 10, 661, 10.1017/S1461145707007766 Quera-Salva, 2011, Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients, Int. Clin. Psychopharmacol., 26, 252, 10.1097/YIC.0b013e328349b117 Racagni, 2011, Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors, World J. Biol. Psychiatry, 12, 574, 10.3109/15622975.2011.595823 Rief, 2009, Meta-analysis of the placebo response in antidepressant trials, J. Affect. Disord., 118, 1, 10.1016/j.jad.2009.01.029 Servier. Report including additional analyses: efficacy and safety of agomelatine (25mg) given orally once a day for 6 weeks versus fluoxetine (20mg) in in- or out-patients with Major Depressive Disorder. A randomised double-blind, placebo controlled parallel-group study. 18week optional treatment period.Data from European Medicines Authority.StudyCL3-20098-022. Servier, Unpublished results. Efficacy and safety of agomelatine (25mg) given orally once a day for 6 weeks versus paroxetine, in patients with Major Depressive Disorder. A randomised, double-blind, placebo-controlled - parallel groups study, 18-weeks extension period. Data from European Medicines Authority. Study CL3-20098-023. Servier, Unpublished results. Efficacy and safety of agomelatine given orally once a day for 6 weeks in patients with Major Depressive Disorder. Confirmation of the efficacy of the agomelatine 25mg dosage and study of the efficacy of agomelatine 50mg dosage. A randomised, double-blind, placebo-controlled, versus fluoxetine, parallel groups study. 18-week continuation period.Data from European Medicines Authority. CL3-20098-024. Servier, Unpublished results. Efficacy and safety of agomelatine (25mg) given orally once a day for 6 weeks in elderly patients with Major Depressive Disorder. A randomised, double-blind, placebo-controlled, parallel-group study with a 18-week extension period. Data from European Medicines Authority. Study CL3-20098-026. Servier Laboratories, Unpublished results. Efficacy of Agomelatine (25–50 mg per day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period. A randomised, double blind, flexible- dose international multi-centre study with parallel groups versus Paroxetine (20–30mg per day). Twelve week treatment plus optional continuation for 12 weeks. CL3-20098-048—Agomelatine (Servier Data on File). Servier Laboratories, Unpublished results. Effects of Agomelatine versus Escitalopram on emotional experiences in out-patients suffering from Major depressive disorder. An exploratory, randomised, double-blind, international, multicentre study with parallel groups: Agomelatine (25–50mg per day) versus Escitalopram (10–20mg per day) over a 6-month period. CL3-20098-060—Agomelatine (Servier Data on File). Servier Laboratories, Unpublished results. Evaluation of efficacy and clinical benefit of agomelatine (25–50mg per day)over 6-month treatment period in patients with major depressive disorder. A randomised, double blind, international multi-centre study with parallel groups versus Duloxetine (60mg per day). Twenty- four weeks of treatment. CL3-20098-062—Agomelatine (Servier Data on File). Shu, 2014, Comparable efficacy and safety of 8 weeks treatment with agomelatine 25–50 mg or fluoxetine 20–40 mg in Asian out-patients with major depressive disorder, Asian J. Psychiatry, 8, 26, 10.1016/j.ajp.2013.09.009 Singh, 2012, Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal, Int. J. Neuropsychopharmacol., 15, 417, 10.1017/S1461145711001301 Stahl, 2010, Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial, J. Clin. Psychiatry, 71, 616, 10.4088/JCP.09m05471blu Taylor, 2014, Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies, Br. Med. J., 348, 1888, 10.1136/bmj.g1888 Theo Vos, 2020, Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet, 369, 1204 Trowman, 2007, The impact of trial baseline imbalances should be considered in systematic reviews: a methodological case study, J. Clin. Epidemiol., 60, 1229, 10.1016/j.jclinepi.2007.03.014 Turner, 2008, Selective publication of antidepressant trials and its influence on apparent efficacy, N. Engl. J. Med., 358, 252, 10.1056/NEJMsa065779 Udristoiu, 2016, Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25–50 mg/day) and escitalopram (10–20 mg/day) in outpatients with major depressive disorder. A 12-week randomised double-blind comparative study, J. Affect. Disord., 199, 6, 10.1016/j.jad.2016.03.048 Vahia V., Yadav A., Unpublished results. Efficacy and safety of agomelatine with flexible dose (25 mg/day with blinded potential adjustment at 50 mg) given orally for 8 weeks in Indian outpatients with major depressive disorder. A randomised double-blind national multicentric study with parallel groups, versus sertraline (50 mg/day with blinded potential adjustment at 100 mg). CL3-20098-074. Data from European Medicines Authority. Yu, 2018, Efficacy and safety of agomelatine vs paroxetine hydrochloride in Chinese Han patients with major depressive disorder: a multicentre, double-blind, noninferiority, randomized controlled trial, J. Clin. Psychopharmacol., 38, 226, 10.1097/JCP.0000000000000878 Zajecka, 2010, Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial, J. Clin. Psychopharmacol., 30, 135, 10.1097/JCP.0b013e3181d420a7